Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy
options. Each resulting cost–effectiveness ratio represents the magnitude of additional …

Abstract Objective The Swedish Dental and Pharmaceutical Benefits Agency (TLV) is the
government body responsible for deciding whether outpatient drugs are to be included in …

Background In Canada, the Canadian Agency for Drugs and Technologies in Health
(CADTH) evaluates and makes recommendations for the reimbursement of cancer drugs …

With the proliferation of affordable large‐scale human genomic data come profound and
vexing questions about management of such data and their clinical uncertainty. These …

Concern over pricing of pharmaceuticals and other health technologies in both high-and low-
income countries is not new. It has been high on the World Health Organization (WHO) …

Background. Scientific advances have led to the discovery of novel treatments with high
prices. The cost to publicly fund high-cost drugs may threaten the sustainability of drug …

Background This study aimed to describe the clinical and cost-effectiveness evidence
supporting reimbursement decisions of new cancer drugs and analyze the influence of trial …

Background Canada has two health technology assessment (HTA) agencies responsible for
oncology drug funding recommendations: the Institut National d'Excellence en Santé et …

Background Drug pricing is an example of a priority setting in a developing country with
official requirements for the use of cost-effectiveness (CE) evidence. Objective To describe …

Objectives The South Korean government required the submission of economic evidence
when it implemented the Positive-List System in December 2006. This study investigates the …